Logo Logo

Publications by Witzens-Harig, M.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Jump to: 2018 | 2017 | 2016
Number of items: 3.


Rule, S.; Jurczak, W.; Jerkeman, M.; Rusconi, C.; Trneny, M.; Offner, F.; Caballero, D.; Joao, C.; Witzens-Harig, M.; Hess, G.; Bence-Bruckler, I.; Cho, S-G; Thieblemont, C.; Zhou, W.; Henninger, T.; Goldberg, J.; Vermeulen, J.; Dreyling, M. (2018): Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. In: Leukemia, Vol. 32, No. 8: pp. 1799-1803


Davies, A.; Trask, P.; Demeter, J.; Florschütz, A.; Hänel, M.; Hong, X.; Kinoshita, T.; Pettengell, R.; Quach, H.; Robinson, S.; Sadullah, S.; Sancho, J.-M.; Udvardy, M.; Witzens-Harig, M.; Rufibach, K.; Zeuner, H.; Unterhalt, M. (2017): Health-Related Quality Of Life Results From The Phase III Gallium Study Of Obinutuzumab-Based And Rituximab-Based Therapy In Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma. In: Haematologica, Vol. 102: pp. 190-191


Witzens-Harig, M.; Keller, U.; Viardot, A.; Buske, C.; Hönig, E.; Crombe, A.; Brandt, J.; Meissner, J.; Ho, A.; La Rosee, P.; Marks, R.; Dreyling, M.; Hess, G. (2016): Safety and clinical activity of temsirolimus in combination with Rituximab and DHAP in patients with relapsed or refractory diffuse large B-cell lymphoma - preliminary results of the storm trial. In: Haematologica, Vol. 101: p. 390

This list was generated on Thu Jul 2 00:38:17 2020 CEST.